| Dr Gazanfar Rahmathulla, MD | |
|
1400 Bellinger St, Eau Claire, WI 54703-5222 | |
| (715) 838-5222 | |
| Not Available |
| Full Name | Dr Gazanfar Rahmathulla |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 26 Years |
| Location | 1400 Bellinger St, Eau Claire, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073750303 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System Eau Claire Hospital | Eau claire, WI | Hospital |
| Mayo Clinic Health System-northland | Barron, WI | Hospital |
| Mayo Clinic Health System-red Cedar Inc | Menomonie, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-northwest Wisconsin Region Inc | 4385553627 | 623 |
News Archive
A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated, the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths.
Protalex, Inc, a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases, today announced enrollment of the first patients in the 3rd cohort of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA) being conducted in South Africa. The dose was increased by a factor of two from the 2nd cohort.
A modified poliovirus therapy that is showing promising results for patients with glioblastoma brain tumors works best at a low dosage, according to the research team at Duke's Preston Robert Tisch Brain Tumor Center where the investigational therapy is being pioneered.
Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.
› Verified 3 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235588831 PECOS PAC ID: 4385553627 Enrollment ID: O20161109002075 |
News Archive
A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated, the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths.
Protalex, Inc, a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases, today announced enrollment of the first patients in the 3rd cohort of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA) being conducted in South Africa. The dose was increased by a factor of two from the 2nd cohort.
A modified poliovirus therapy that is showing promising results for patients with glioblastoma brain tumors works best at a low dosage, according to the research team at Duke's Preston Robert Tisch Brain Tumor Center where the investigational therapy is being pioneered.
Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gazanfar Rahmathulla, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Dr Gazanfar Rahmathulla, MD 1400 Bellinger St, Eau Claire, WI 54703-5222 Ph: (715) 838-5222 |
News Archive
A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated, the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths.
Protalex, Inc, a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases, today announced enrollment of the first patients in the 3rd cohort of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA) being conducted in South Africa. The dose was increased by a factor of two from the 2nd cohort.
A modified poliovirus therapy that is showing promising results for patients with glioblastoma brain tumors works best at a low dosage, according to the research team at Duke's Preston Robert Tisch Brain Tumor Center where the investigational therapy is being pioneered.
Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.
› Verified 3 days ago
Terry K Schiefer, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Dr. Eduardo J Perez, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Jonathan M Bledsoe, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Gary L Gasser, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 900 W Clairemont Ave, Eau Claire, WI 54701 Phone: 715-858-1777 | |
Mark Pichelmann, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-3311 |